Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Interest & Investment Income (2019 - 2025)

Benitec Biopharma has reported Interest & Investment Income over the past 7 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Interest & Investment Income at $1.4 million for Q4 2025, up 68.89% from a year ago — trailing twelve months through Dec 2025 was $4.3 million (up 81.82% YoY), and the annual figure for FY2025 was $3.3 million, up 263.5%.
  • Interest & Investment Income reached $1.4 million in Q4 2025 per BNTC's latest filing, up from $1.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.4 million in Q4 2025 and bottomed at -$11000.0 in Q4 2021.
  • Median Interest & Investment Income over the past 5 years was -$3000.0 (2021), compared with a mean of $326150.0.
  • The largest annual shift saw Interest & Investment Income crashed 900.0% in 2022 before it surged 20675.0% in 2025.
  • Over 5 years, Interest & Investment Income stood at -$11000.0 in 2021, then increased by 18.18% to -$9000.0 in 2022, then surged by 33.33% to -$6000.0 in 2023, then skyrocketed by 13816.67% to $823000.0 in 2024, then soared by 68.89% to $1.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for BNTC at $1.4 million in Q4 2025, $1.0 million in Q3 2025, and $1.0 million in Q2 2025.